To include your compound in the COVID-19 Resource Center, submit it here.

Genentech's Tecentriq meets PFS endpoint in first-line NSCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said Tecentriq atezolizumab (MPDL3280A, RG7446) met the co-primary endpoint of improving progression-free survival (PFS) in the Phase III IMpower150 trial as first-line treatment of advanced stage IV non-squamous non-small cell lung cancer

Read the full 406 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE